Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

NCT05010629 is registered in ClinicalTrials.gov with Glenn J. Hanna as lead sponsor.

NCT NCT05010629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05010629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Lead sponsor
Glenn J. Hanna
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 17, 2021
Completion date
April 12, 2027
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, metastatic cancer, recurrent salivary gland cancer, salivary gland cancer